Lindbrook Capital, LLC Maxcyte, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 237 shares of MXCT stock, worth $993. This represents 0.0% of its overall portfolio holdings.
Number of Shares
237
Previous 116
104.31%
Holding current value
$993
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$34.3 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$34.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$24.2 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$21.1 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$20.2 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $426M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...